Approval · Notice of Compliance 34069 · 2024
ILLUCCIX: Notice of Compliance 34069
Issued September 20, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34069
- Date
- September 20, 2024
- Company
- Telix Pharmaceuticals (Us) IncFishers, Indiana, United States
- Product type
- Radiopharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Extension of an indication: Use with the positron emission tomography (PET) of prostate specific membrane antigen (PSMA) positive lesions in men with prostate cancer: - For identification of patients with progressive metastatic castration-resistant prostate cancer (mCRPC), for whom PSMA-targeted therapy is indicated
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ILLUCCIX | Not yet assigned | — |
Medicinal ingredients
- GALLIUM (68GA) GOZETOTIDE 25 MCG per VIAL